• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

托珠单抗在一名细胞因子释放综合征的COVID-19患者中的疗效

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome.

作者信息

Uslu Sadettin

机构信息

Department of Rheumatology, Ömer Halisdemir University Bor Physical Medicine and Rehabilitation, Training and Research Hospital, Niğde, Turkey.

出版信息

Eur J Case Rep Intern Med. 2020 May 22;7(6):001731. doi: 10.12890/2020_001731. eCollection 2020.

DOI:10.12890/2020_001731
PMID:32523930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7279911/
Abstract

UNLABELLED

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.

LEARNING POINTS

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by COVID-19.CRS can be life-threatening in severe COVID-19.Tocilizumab may have a role in treating severe COVID-19 patients with CRS.

摘要

未标注

细胞因子释放综合征（CRS）是一种全身性炎症反应，可由多种因素触发，如感染。2019冠状病毒病（COVID-19）患者的CRS危及生命，且在COVID-19诊断后可能很快发生。托珠单抗（TCZ）是一种白细胞介素-6（IL-6）抑制剂，可能改善与重症COVID-19相关的CRS，从而改善临床结局。我们报告一例由COVID-19感染引起的危及生命的CRS病例，经TCZ成功治疗。

学习要点

细胞因子释放综合征（CRS）是一种可由COVID-19触发的全身性炎症反应。CRS在重症COVID-19中可能危及生命。托珠单抗可能在治疗患有CRS的重症COVID-19患者中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/e496cf2a7cbb/1731_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/1fe284ac26d2/1731_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/56104550aff1/1731_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/e496cf2a7cbb/1731_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/1fe284ac26d2/1731_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/56104550aff1/1731_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/008c/7279911/e496cf2a7cbb/1731_Fig3.jpg

相似文献

1
Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome.托珠单抗在一名细胞因子释放综合征的COVID-19患者中的疗效
Eur J Case Rep Intern Med. 2020 May 22;7(6):001731. doi: 10.12890/2020_001731. eCollection 2020.
2
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.托珠单抗治疗重症新型冠状病毒肺炎及伴发的细胞因子释放综合征
Eur J Case Rep Intern Med. 2020 Apr 22;7(5):001675. doi: 10.12890/2020_001675. eCollection 2020.
3
Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?托珠单抗：阻止2019冠状病毒病（COVID-19）诱导的细胞因子释放综合征（CRS）的关键？
Front Med (Lausanne). 2020 Oct 26;7:571597. doi: 10.3389/fmed.2020.571597. eCollection 2020.
4
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.白细胞介素-6 转导信号诱导细胞因子释放综合征中的血管内皮细胞产生纤溶酶原激活物抑制剂-1。
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351-22356. doi: 10.1073/pnas.2010229117. Epub 2020 Aug 21.
5
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.美国食品和药物管理局批准概要：托西珠单抗治疗嵌合抗原受体 T 细胞引起的严重或危及生命的细胞因子释放综合征。
Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.
6
Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.托珠单抗与新冠病毒肺炎细胞因子释放综合征：来自巴基斯坦一家单一中心的经验
Cureus. 2021 Dec 6;13(12):e20219. doi: 10.7759/cureus.20219. eCollection 2021 Dec.
7
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.托珠单抗治疗 COVID-19 住院患者细胞因子释放综合征：生存和临床结局。
Chest. 2020 Oct;158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006. Epub 2020 Jun 15.
8
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
9
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.托珠单抗在一名重症 COVID-19 患者中引起的急性高甘油三酯血症
Intern Med. 2020 Nov 15;59(22):2945-2949. doi: 10.2169/internalmedicine.5244-20. Epub 2020 Sep 19.
10
Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.托珠单抗用于治疗新冠病毒感染细胞因子释放综合征：两个中心的回顾性研究
Indian J Crit Care Med. 2020 Sep;24(9):771-776. doi: 10.5005/jp-journals-10071-23566.

引用本文的文献

1
When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak.当免疫反应失控：SARS-CoV-2 爆发的教训。
Front Immunol. 2021 Sep 24;12:692598. doi: 10.3389/fimmu.2021.692598. eCollection 2021.

本文引用的文献

1
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?我们能否使用白细胞介素 6（IL-6）阻断剂治疗 2019 冠状病毒病（COVID-19）引起的细胞因子释放综合征（CRS）？
J Autoimmun. 2020 Jul;111:102452. doi: 10.1016/j.jaut.2020.102452. Epub 2020 Apr 10.
2
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.美国食品和药物管理局批准概要：托西珠单抗治疗嵌合抗原受体 T 细胞引起的严重或危及生命的细胞因子释放综合征。
Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.